Aging population's higher drug sales
A report by research group IMS Health has shown the effect of aging populations, with total pharmaceutical sales up 7% in 2005, while sales in Australia and New Zealand increased 4%, driven by blockbuster drugs, ie, those with turnover above $1.0 billion annually.
Sales of drugs to treat age-related illnesses, including cardiovascular disease and cancer, topped $600.0 billion last year. The world's most-used drug, Lipitor (atorvastatin), with worldwide revenues exceeding $1.0 billion of the global $32.0 billion cholesterol-reduction market, was also Australia's biggest-selling drug.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze